Controlled extension of oral antidiabetic therapy on former insulin dependent diabetics by means of the combined i.v. glibenclamide-glucose-response-test.
D000284:Administration, Oral; D000328:Adult; D000367:Age Factors; D000368:Aged; D002986:Clinical Trials as Topic; D003920:Diabetes Mellitus / Q000175:diagnosis / Q000188:drug therapy*; D004338:Drug Combinations; D004351:Drug Resistance; D005260:Female; D005947:Glucose / Q000008:administration & dosage; D005905:Glyburide / Q000008:administration & dosage / Q000627:therapeutic use; D006432:Hemochromatosis / Q000150:complications; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007275:Injections, Intravenous; D007328:Insulin / Q000097:blood; D007330:Insulin Antibodies / Q000032:analysis; D008297:Male; D008722:Methods; D008875:Middle Aged; D011379:Prognosis; D013453:Sulfonylurea Compounds / Q000627:therapeutic use*; D014044:Tolbutamide / Q000627:therapeutic use
D004338:Drug Combinations; D007004:Hypoglycemic Agents; D007328:Insulin; D007330:Insulin Antibodies; D013453:Sulfonylurea Compounds; D014044:Tolbutamide; D005947:Glucose; D005905:Glyburide